SEARCH:   Advanced

Blood, 1 May 2007, Vol. 109, No. 9, pp. 3672-3675. Prepublished online as a Blood First Edition Paper on January 5, 2007; DOI 10.1182/blood-2006-08-042929. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-08-042929v1 109/9/3672    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Robak, T. Articles by Konopka, L. Search for Related Content PubMed PubMed Citation Articles by Robak, T. Articles by Konopka, L. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted August 21, 2006 Accepted December 30, 2006 Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial Tadeusz Robak*, Krzysztof Jamroziak, Joanna Gora-Tybor, Jerzy Z. Blonski, Marek Kasznicki, Jadwiga Dwilewicz-Trojaczek, Elzbieta Wiater, Andrzej Zdunczyk, Jacek Dybowicz, Anna Dmoszynska, Maria Wojtaszko, Barbara Zdziarska, Malgorzata Calbecka, Aleksandra Kostyra, Andrzej Hellmann, Krzysztof Lewandowski, Beata Stella-Holowiecka, Kazimierz Sulek, Krzysztof Gawronski, Aleksander B. Skotnicki, Wieslaw Nowak, Krystyna Zawilska, Lucyna Molendowicz-Portala, Janusz Kloczko, Jaroslaw Sokolowski, Krzysztof Warzocha, Ilona Seferynska, Bernardeta Ceglarek, and Lech Konopka Department of Hematology, Medical University of Lodz, Lodz, Poland Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland Department of Hematology, City Hospital, Krakow, Poland Department of Hematology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland Department of Hematology, Pomeranian Medical University, Szczecin, Poland Department of Hematology, City Hospital, Torun, Poland Department of Hematology, Medical University of Gdansk, Gdansk, Poland Department of Hematology and Bone Marrow Transplantation, Medical University, Katowice, Poland Department of Internal Medicine, Military Institute of Medicine, Warsaw, Poland Department of Hematology, Jagiellonian University, Krakow, Poland Department of Hematology, Medical University of Poznan, Poznan, Poland Department of Hematology, Medical University of Bialystok, Bialystok, Poland Institute of Hematology and Transfusiology, Warsaw, Poland and Polish Adult Leukemia Group, Warsaw, Poland * Corresponding author; email: robaktad{at}csk.umed.lodz.pl. Cladribine (2-chlorodeoxyadenosine, 2-CdA) treatment-associated infections may shorten potentially long-term survival in hairy cell leukemia (HCL). In search of optimal mode of 2-CdA administration, 132 patients with untreated HCL were randomized to receive either standard 5-day 2-CdA protocol or novel schedule of six weekly 2-CdA infusions suggested to be less toxic. Analysis of treatment response confirmed similar complete remission rates, overall response rates, progression-free survival and overall survival in both 2-CdA protocols. However, we did not observe lower toxicity of weekly schedule. Of special interest, no significant differences were found in rate of grade 3/4 infections (18% for daily and 26% for weekly protocol, difference=-8.2% (95%confidence interval -23.2 to 6.9%), p=0.28) and rate of septic deaths (3% for daily and 2% for weekly protocol, difference=1.4% (95% confidence interval -4.3 to 7.0%), p=0.64). In conclusion, HCL treatment with weekly 2-CdA infusions is equally effective, but no safer than standard 5-day 2-CdA protocol. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. Forconi, E. Sozzi, E. Cencini, F. Zaja, T. Intermesoli, C. Stelitano, L. Rigacci, F. Gherlinzoni, R. Cantaffa, A. Baraldi, et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior Blood, November 19, 2009; 114(21): 4696 - 4702. [Abstract] [Full Text] [PDF] Cladribine Therapy for Hairy Cell Leukemia: Does Schedule Matter? Journal Watch Oncology and Hematology, May 25, 2007; 2007(525): 1 - 1. [Full Text]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020